White Paper
New study of Angel® yeast beta-glucan shows efficacy in improving Alzheimer's disease by regulating gut microbiota and metabolites
A recent study published by Angel Yeast Co., Ltd. on International Journal of Biological Macromolecules attracted much attention. Researchers found that yeast beta-glucan was related to a series of gut-brain axis events and can improve neuroinflammation and brain insulin resistance, which means that yeast beta-glucan may prevent Alzheimer's disease. This study broadened the potential applications of yeast beta-glucan as a novel dietary supplement to prevent early-stage pathologies associated with AD.
Yeast beta-glucan is a polysaccharide derived from Saccharomyces cerevisiae, with featured molecular structure of a linear beta-(1, 3)-glucan backbone with beta-(1, 6)-linked side chains. It shows stronger biological activities than other sources of beta-glucans especially in immunity enhancing. “Nowadays, AD has become a global healthy problem, this study unveiled the relationship between yeast beta-glucan and AD, presenting a potential way to improve AD.” Said Poshy Zhang, R&D director of Angel Yeast Human Health Division.
